Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol

Introduction Immunotherapy with checkpoint inhibitors (CPIs) has revolutionised cancer treatment but has no convincing effect in metastatic castration-resistant prostate cancer (mCRPC). It has been suggested that a combination of CPI and hypofractionated stereotactic body radiotherapy (SBRT) may wor...

Full description

Bibliographic Details
Main Authors:	Henriette Lindberg, Inge Marie Svane, Estrid V Hogdall, Dorte Lisbeth Nielsen, Susann Theile, Nicklas Juel Spindler, Gitte Fredberg Persson, Gina Al-Farra, Helle Westergren Hendel, Torben Lorentzen, Rikke Løvendahl Eefsen
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-01-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/13/1/e063500.full

Similar Items

Isolated asymptomatic masseter muscle metastasis as first sign of metastatic disease in a patient with known melanoma
by: Caroline Asirvatham Gjorup, et al.
Published: (2016-12-01)

The IGF–PAPP-A–Stanniocalcin Axis in Serum and Ascites Associates with Prognosis in Patients with Ovarian Cancer
by: Rikke Hjortebjerg, et al.
Published: (2024-02-01)

The influence of insulin-related genetic variants on fetal growth, fetal blood flow, and placental weight in a prospective pregnancy cohort
by: Pauline K. Reim, et al.
Published: (2023-11-01)

Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression
by: Sif Homburg, et al.
Published: (2024-02-01)

Fractionated palliative thoracic radiotherapy in non-small cell lung cancer – futile or worth-while?
by: Malene Støchkel Frank, et al.
Published: (2018-01-01)

Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project
by: Julie L. Hentze, et al.
Published: (2017-12-01)

Next Generation Sequencing Technology in the Clinic and Its Challenges
by: Lau K. Vestergaard, et al.
Published: (2021-04-01)

Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour
by: Charlotte Brinch, et al.
Published: (2021-11-01)

The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis
by: Kasper Ingerslev, et al.
Published: (2017-05-01)

Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus
by: Lau K. Vestergaard, et al.
Published: (2021-10-01)

Haemodialysis nurses' occupational health and work‐related musculoskeletal hand pain after work: A cluster analysis
by: Eva Westergren, et al.
Published: (2023-06-01)

The somatic mode: doing good in targeted cancer therapy
by: Ivana Bogicevic, et al.
Published: (2021-04-01)

The prevalence of EBV and CMV DNA in epithelial ovarian cancer
by: Kasper Ingerslev, et al.
Published: (2019-02-01)

Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
by: Kira Philipsen Prahm, et al.
Published: (2018-01-01)

Effects of particulate matter on atherosclerosis: a link via high-density lipoprotein (HDL) functionality?
by: Siri A. N. Holme, et al.
Published: (2020-08-01)

Circulating antinuclear antibodies in patients with pelvic masses are associated with malignancy and decreased survival.
by: Niels H H Heegaard, et al.
Published: (2012-01-01)

Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
by: Joanna Lopacinska-Jørgensen, et al.
Published: (2021-01-01)

Test of an Improved DNA and RNA Purification Protocol—Importance of Proteinase K and Co-Purified Small RNAs
by: Edyta Biskup, et al.
Published: (2022-10-01)

Strategies for data normalization and missing data imputation and consequences for potential diagnostic microRNA biomarkers in epithelial ovarian cancer.
by: Joanna Lopacinska-Jørgensen, et al.
Published: (2023-01-01)

Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures
by: Douglas V. N. P. Oliveira, et al.
Published: (2021-10-01)

Gene expression profile association with poor prognosis in epithelial ovarian cancer patients
by: Douglas V. N. P. Oliveira, et al.
Published: (2021-03-01)

The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients
by: Sara Bønløkke, et al.
Published: (2022-07-01)

Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience
by: Gry Assam Taarnhøj, et al.
Published: (2021-04-01)

Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy
by: Gry Assam Taarnhøj, et al.
Published: (2019-08-01)

Potential Targeted Therapies in Ovarian Cancer
by: Yagmur Sisman, et al.
Published: (2022-10-01)

The Role of US Contrast Agents in US-Guided Biopsy of Focal Liver Lesions: A Pictorial Review
by: Torben Lorentzen, et al.
Published: (2019-01-01)

MicroRNA Biomarkers in IBD—Differential Diagnosis and Prediction of Colitis-Associated Cancer
by: Jaslin P. James, et al.
Published: (2020-10-01)

A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden.
by: Lasse Kjær, et al.
Published: (2012-01-01)

Samtaler i korpusformat
by: Philip Diderichsen, et al.
Published: (2023-12-01)

Individualized telerehabilitation for heart patients across municipalities, hospitals and medical disciplines: preliminary findings from the Teledialog project
by: Birthe Dinesen, et al.
Published: (2014-11-01)

Individualized telerehabilitation for heart patients across municipalities, hospitals and medical disciplines: preliminary findings from the Teledialog project
by: Birthe Dinesen, et al.
Published: (2014-11-01)

Quantitative MRI and Clinical Assessment of Muscle Function in Adults With Cerebral Palsy
by: Christian Svane, et al.
Published: (2021-11-01)

miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer
by: Boye Schnack Nielsen, et al.
Published: (2014-08-01)

Interventions for Nursing Home Residents with Dysphagia—A Scoping Review
by: Dorte Melgaard, et al.
Published: (2021-05-01)

Clinic for Multimorbidity: An Innovative Approach to Integrate General Practice and Specialized Health Care Services
by: Cathrine Bell, et al.
Published: (2023-06-01)

Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
by: Douglas Nogueira Perez Oliveira, et al.
Published: (2019-01-01)

Individualizing the Oncological Treatment of Patients With Metastatic Non–Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO Study
by: Ida Marie Lind Rasmussen, et al.
Published: (2022-09-01)

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
by: Jakob V Schou, et al.
Published: (2014-01-01)

Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
by: Mette Ølgod Pedersen, et al.
Published: (2017-01-01)

Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer
by: Karen-Lise Garm Spindler, et al.
Published: (2018-11-01)